Codexis, Inc. · NASDAQ:CDXS
Codexis — Investor Presentation (September 2017)
23 slides from Codexis's investor presentation, Sep 8, 2017
Slide 1: Unlock the power of proteins: Codexis Corporate Presentation
Unlock the power of proteins TM Codexis Corporate Presentation September 2017 Nasdaq: CDXS 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and o
Slide 3: Welcome to the Protein Revolution
Welcome to the Protein Revolution 3
Slide 4: Digital Revolution, Genomics Revolution
4 Digital Revolution genomics revolution digital revolution moore?s law genomics revolution estimated based on historical growth rate desktop computer laptop computer smart phone current capacity human genome project 1970 1980 2000 2010 2020
Slide 5: Complexity of Protein Structure—Function Relationships
Complexity of Protein Structure—Function Relationships DNA Code Protein Structure Protein Function Infinitely Complex 5
Slide 6: The Protein Revolution – Now Is the Time
The Protein Revolution ? Now Is the Time High DNA Protein Artificial Throughput Sequencing Revolution Intelligence Screening 6
Slide 7: Codexis – Leading The Protein Revolution
Codexis ? Leading The Protein Revolution Company History Cumulative Investments Employees 15+ Years > $500m ~115 (65 in R&D) Patents & Applications Protein Project Pipeline * Growing Revenues > 900 worldwide 8 Proteins Commercialized $49m in 2016 + 25 Pre-Commercial (+44% y-o-y) 18% CA
Slide 8: CodeEvolver—Technological Tool of the Protein Revolution
CodeEvolver—Technological Tool of the Protein Revolution 8 high throughtput screening human expertise dna sequencing artificial intelligence function-driven mutations
Slide 9: Project speed driving Codexis growth
Project speed driving codexis growth 40 scientists years per project 10 scientists years per project 2 scientists years per project future continued acceleration 2000 2005 2010 2015 9
Slide 10: A Growing List of Markets Served
A Growing List of Markets Served Pharmaceuticals food ingredients biotherapeutics future applications molecular diagnostics industrial enzymes 10
Slide 11: Productivity Improvements Reduce CAPEX
Productivity Improvements Reduce CAPEX SOLUTION Capacity constraints in existing supply chain From zero activity to commercial targets in <12 months 53% higher productivity 19% reduction in energy usage Expensive, toxic chemo-catalyst replaced No new factory needed ? [Codexis] helped avoid the co
Slide 12: CodeEvolver Licensing Creates Value Across Portfolio
CodeEvolver Licensing Creates Value Across Portfolio SOLUTION How to effectively leverage protein Licensed the CodeEvolver platform engineering to improve GSK?s portfolio? Deeply embedded the technology in house Applications from discovery to post launch Codexis earns front end and back end economic
Slide 13: Rapid Product Launch Enabled by Cost-Efficient Process
Rapid Product Launch Enabled by Cost-Efficient Process CHALLENGE SOLUTION Healthier food ingredient requires a Commercial targets met in 7 months lower cost process to enable the 20-fold catalyst stability improvement product launch 90+% reduction in catalyst system cost Enabled commercial productio
Slide 14: Therapeutic Enzyme to Treat Phenylketonuria (PKU)
Therapeutic Enzyme to Treat Phenylketonuria (PKU) CHALLENGE SOLUTION Besides aggressive dietary control, First CodeEvolver drug discovery breakthrough no available treatment for > 80% of GI tract enables oral dosage Stability in convenient PKU patients > 50-fold stability improvement, in vitro
Slide 15: Improving Sensitivity and Precision in Molecular Diagnostics
Improving Sensitivity and Precision in Molecular Diagnostics CHALLENGE SOLUTION Create more sensitive, fluid-based Codexis engineered enzymes for next gen diagnostic tests: earlier, less sequencing with greater sensitivity and precision invasive cancer detection Detection of very, very low concentra
Slide 16: Codexis: Monetizing The Protein Revolution
Codexis: Monetizing The Protein Revolution Proven Revenue Generation & Partnering Approaches Engineer proteins sell proteins major partnerships biotherapeutics discovery 16
Slide 17: Growing R&D Revenues
Growing R&D Revenues * Excludes CodeEvolver milestone revenue and the one-time 4Q?15 royalty settlement but includes amortized upfront revenues from CodeEvolver platform licensees. 17
Slide 18: Growing Product Revenue and Expanding Margins
Growing Product Revenue and Expanding Margins * 2017 Guidance Range Provided on August 9, 2017 18
Slide 19: Growing list of major partnerships driving growth
Growing list of major partnerships driving growth partner type of partnering deal gsk merck t&l (march 17 deal) 2h?17 new partner another new major partner code evolver platform major product (food ingredient) target 2014 2015 2016 2017 2018+ 19
Slide 20: Codexis Biotherapeutics Pipeline
Codexis Biotherapeutics Pipeline PKU CDX-6114 Drug Target 1 (DT1) DT2 DT3 DT4 Step-out opportunities from monetizing biotherapeutics pipeline 20
Slide 21: Consistently Growing Total Revenues
Consistently Growing Total Revenues * 2017 Guidance Range Provided on August 9, 2017 21
Slide 22: Codexis Investment Summary
Codexis Investment Summary Protein Revolution Leadership $500+ million invested over 15+ years Every project adds to CodeEvolver knowledge base and enhances value Deep Relationships with Industry Leaders Multiple revenue streams validate the CodeEvolver technology platform Further upside in molecula
Slide 23: Contact Us
Contact Us John Nicols President & Chief Executive Officer john.nicols@codexis.com (650) 421-2388 Gordon Sangster Corporate Headquarters Senior Vice President & Chief Financial Officer 200 Penobscot Drive gordon.sangster@codexis.com Redwood City, CA 94063 (650) 421-8115 USA Jody Cain Lippert